MGM Resorts International (NYSE:MGM) has 0.10% insider ownership while its institutional ownership stands at 71.70%. In last trading activity company’s stock closed at $22.00. MGM Resorts International (NYSE:MGM), the company building an $800-million-resort casino in Springfield’s South End, stated Mon. in that a hedge fund’s proposed changes to the best way MGM does business are confined and short-sighted. The 32-page report, issued Mon. on MGM’s investor relations web site, makes just one reference to MGM Springfield.
Best Buy Co., Inc. (NYSE:BBY) in last trading activity decreased -2.05% to close at $35.39. Company weekly performance is -2.93% while its quarterly performance stands at 2.92%. Best Buy Co., Inc. (NYSE:BBY) is -14.62% away from its 52 week high. Best Buy Co (NYSE:BBY) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday.
On last trading day IAMGOLD Corp. (NYSE:IAG) fell -1.40% to close at $2.12. Its volatility for the week is 4.66% while volatility for the month is 4.88%. IAG’s sales growth for past 5 years was 2.00% and its EPS growth for past 5 years was -42.10%. IAMGOLD Corp. (NYSE:IAG) monthly performance is 1.44%. IAMGOLD Corporation (NYSE:IAG) will release its first quarter 2015 financial results after market hours on Tuesday, May 5th, 2015.
RMG Networks Holding Corporation (NASDAQ:RMGN) has 51.95% insider ownership while its institutional ownership stands at 38.90%. In last trading activity company’s stock closed at $1.61. On 16 April, RMG Networks Holding Corporation (NASDAQ:RMGN) announced the introduction of its new Labor Productivity Improvement solution for supply chain warehouses and distribution centers that is designed to improve supply chain efficiency by up to 20 percent.
Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity decreased -1.44% to close at $103.69. Company weekly performance is 2.28% while its quarterly performance stands at -1.75%. Gilead Sciences Inc. (NASDAQ:GILD) is -11.24% away from its 52 week high. Gilead Sciences, Inc. (NASDAQ:GILD) announced results from two studies evaluating the safety and efficacy of investigational uses of sofosbuvir-based regimens in chronic hepatitis C virus (HCV)-infected patients with genotypes 2, 3, 4 and 5. Results from the BOSON study of Sovaldi® (sofosbuvir 400 mg) in combination with ribavirin (RBV) or with pegylated interferon (PEG)/RBV demonstrated high cure rates across all patients with genotypes 2 and 3.